# Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

> **NCT04314544** · PHASE3 · COMPLETED · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 508 (actual)

## Conditions studied

- Active Psoriatic Arthritis

## Interventions

- **DRUG:** TILD
- **DRUG:** matching placebo injections

## Key facts

- **NCT ID:** NCT04314544
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-01
- **Primary completion:** 2025-03-26
- **Final completion:** 2025-12-22
- **Target enrollment:** 508 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04314544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04314544, "Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT04314544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*